Acumen Pharmaceuticals (ABOS) Competitors $2.33 +0.21 (+9.91%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$2.29 -0.04 (-1.67%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. ALMS, ETHZ, LRMR, ACIU, FDMT, ENGN, KMDA, YMAB, AMRN, and TVRDShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Alumis (ALMS), Flag Ship Acquisition (ETHZ), Larimar Therapeutics (LRMR), AC Immune (ACIU), 4D Molecular Therapeutics (FDMT), enGene (ENGN), Kamada (KMDA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Its Competitors Alumis Flag Ship Acquisition Larimar Therapeutics AC Immune 4D Molecular Therapeutics enGene Kamada Y-mAbs Therapeutics Amarin Tvardi Therapeutics Alumis (NASDAQ:ALMS) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership. Is ALMS or ABOS more profitable? Acumen Pharmaceuticals' return on equity of -81.39% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -119.15% -92.50% Acumen Pharmaceuticals N/A -81.39%-61.96% Do analysts recommend ALMS or ABOS? Alumis presently has a consensus price target of $20.17, indicating a potential upside of 335.57%. Acumen Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 200.43%. Given Alumis' stronger consensus rating and higher possible upside, research analysts clearly believe Alumis is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media refer more to ALMS or ABOS? In the previous week, Alumis had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Alumis and 3 mentions for Acumen Pharmaceuticals. Alumis' average media sentiment score of 1.09 beat Acumen Pharmaceuticals' score of 0.83 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, ALMS or ABOS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/AAcumen PharmaceuticalsN/AN/A-$102.33M-$2.28-1.02 Do institutionals and insiders believe in ALMS or ABOS? 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 40.7% of Alumis shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, ALMS or ABOS? Alumis has a beta of -1.47, indicating that its stock price is 247% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. SummaryAlumis beats Acumen Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$128.42M$3.35B$6.04B$10.50BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-1.0221.9084.6427.24Price / SalesN/A263.81508.12197.88Price / CashN/A46.9537.5761.53Price / Book0.7710.4312.256.74Net Income-$102.33M-$52.58M$3.32B$276.59M7 Day Performance23.94%-1.55%-1.34%-0.47%1 Month Performance84.92%12.96%8.14%7.47%1 Year PerformanceN/A15.43%72.27%34.58% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals3.2592 of 5 stars$2.33+9.9%$7.00+200.4%-0.9%$128.42MN/A-1.0220News CoverageAnalyst ForecastALMSAlumis3.564 of 5 stars$4.12+2.5%$20.17+389.5%-55.1%$418.34MN/A0.00N/ANews CoverageETHZFlag Ship AcquisitionN/A$2.55+0.8%N/AN/A$416.01MN/A-0.177Gap UpLRMRLarimar Therapeutics2.9404 of 5 stars$4.81-1.2%$16.71+247.5%-46.2%$403.13MN/A-3.0830ACIUAC Immune1.7761 of 5 stars$3.54-11.3%$10.00+182.5%-3.8%$400.64M$28.92M-6.10140High Trading VolumeFDMT4D Molecular Therapeutics2.4415 of 5 stars$8.40-1.8%$30.40+261.9%+10.4%$399.31M$40K-2.38120News CoverageENGNenGene2.7482 of 5 stars$7.60-1.9%$19.50+156.6%+14.1%$396.74MN/A-4.0031Trending NewsAnalyst ForecastGap UpKMDAKamada4.4812 of 5 stars$6.70-1.8%$13.00+94.0%+29.4%$392.18M$160.95M19.71360News CoverageYMABY-mAbs Therapeutics1.2885 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150AMRNAmarin0.4523 of 5 stars$19.33+2.6%$12.00-37.9%+66.0%$389.66M$228.61M-5.27360High Trading VolumeTVRDTvardi Therapeutics2.8963 of 5 stars$40.18-0.1%$64.25+59.9%N/A$377.25M$7.14M0.0080Trending NewsAnalyst DowngradeGap Down Related Companies and Tools Related Companies ALMS Competitors ETHZ Competitors LRMR Competitors ACIU Competitors FDMT Competitors ENGN Competitors KMDA Competitors YMAB Competitors AMRN Competitors TVRD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
